EVO vs. UNCY
EVO (Evotec SE ADR) and UNCY (Unicycive Therapeutics Inc) are both stocks. Both are in the Healthcare sector — EVO in Drug Manufacturers - Specialty & Generic, UNCY in Biotechnology. Over the past 3 years, EVO returned -39.19%/yr vs -19.17%/yr for UNCY. At a 0.11 correlation, their price movements are largely independent.
Performance
EVO vs. UNCY - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, EVO achieves a -14.94% return, which is significantly lower than UNCY's 36.40% return.
EVO
- 1D
- 2.34%
- 1M
- -13.53%
- YTD
- -14.94%
- 6M
- -12.37%
- 1Y
- -30.32%
- 3Y*
- -39.19%
- 5Y*
- -34.55%
- 10Y*
- 2.48%
UNCY
- 1D
- 14.89%
- 1M
- -2.60%
- YTD
- 36.40%
- 6M
- 34.53%
- 1Y
- 24.13%
- 3Y*
- -19.17%
- 5Y*
- —
- 10Y*
- —
EVO vs. UNCY - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
EVO Evotec SE ADR | -14.94% | -25.96% | -64.54% | 44.99% | -65.94% | 9.52% |
UNCY Unicycive Therapeutics Inc | 36.40% | -27.35% | -8.47% | 60.69% | -73.79% | -58.80% |
Correlation
The correlation between EVO and UNCY is 0.20, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.20 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.14 |
Correlation (All Time) Calculated using the full available price history since Jul 12, 2021 | 0.11 |
Fundamentals
EVO:
$931.36M
UNCY:
$1.88B
EVO:
-€0.29
UNCY:
-$0.37
EVO:
1.00
UNCY:
49.90
EVO:
€786.00M
UNCY:
$0.00
EVO:
€113.49M
UNCY:
$0.00
EVO:
-€34.87M
UNCY:
-$35.07M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
EVO vs. UNCY — Risk / Return Rank
EVO
UNCY
EVO vs. UNCY - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Evotec SE ADR (EVO) and Unicycive Therapeutics Inc (UNCY). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| EVO | UNCY | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -0.89 | ||
| Sortino ratioReturn per unit of downside risk | -1.49 | ||
| Omega ratioGain probability vs. loss probability | 0.93 | 1.13 | -0.19 |
| Calmar ratioReturn relative to maximum drawdown | -0.65 | 0.51 | -1.16 |
| Martin ratioReturn relative to average drawdown | -1.21 | 0.97 | -2.18 |
Loading charts...
Drawdowns
EVO vs. UNCY - Drawdown Comparison
The maximum EVO drawdown since its inception was -91.29%, roughly equal to the maximum UNCY drawdown of -95.97%. Use the drawdown chart below to compare losses from any high point for EVO and UNCY.
Loading charts...
Drawdown Indicators
| EVO | UNCY | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -91.29% | -95.97% | +4.68% |
Max Drawdown (1Y)Largest decline over 1 year | -46.77% | -47.40% | +0.63% |
Max Drawdown (3Y)Largest decline over 3 years | -82.71% | -86.82% | +4.11% |
Max Drawdown (5Y)Largest decline over 5 years | -91.29% | — | — |
Max Drawdown (10Y)Largest decline over 10 years | -91.29% | — | — |
Current DrawdownCurrent decline from peak | -90.12% | -86.55% | -3.57% |
Average DrawdownAverage peak-to-trough decline | -33.88% | -82.89% | +49.01% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 25.10% | 24.91% | +0.19% |
Volatility
EVO vs. UNCY - Volatility Comparison
The current volatility for Evotec SE ADR (EVO) is 15.21%, while Unicycive Therapeutics Inc (UNCY) has a volatility of 27.15%. This indicates that EVO experiences smaller price fluctuations and is considered to be less risky than UNCY based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| EVO | UNCY | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 15.21% | 27.15% | -11.94% |
Volatility (6M)Calculated over the trailing 6-month period | 41.39% | 48.15% | -6.76% |
Volatility (1Y)Calculated over the trailing 1-year period | 53.82% | 74.47% | -20.65% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 58.77% | 119.40% | -60.63% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 51.65% | 119.40% | -67.75% |
Dividends
EVO vs. UNCY - Dividend Comparison
Neither EVO nor UNCY has paid dividends to shareholders.
Financials
EVO vs. UNCY - Financials Comparison
This section allows you to compare key financial metrics between Evotec SE ADR and Unicycive Therapeutics Inc. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
Frequently Asked Questions
EVO and UNCY have a correlation of 0.20, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
UNCY has higher volatility (27.15%) compared to EVO (15.21%). In terms of maximum drawdown, EVO dropped -91.29% vs UNCY's -95.97%.
UNCY currently has the higher Sharpe Ratio (0.33 vs -0.57), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for EVO and UNCY
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer